HomeNewsBusinessMarketsDr Reddy’s Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages

Dr Reddy’s Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages

Vaibhavi Ranjan • July 28, 2023 / 12:14 IST

Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fueled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls.

Dr Reddy's office building

To read the full story,

Are you a PRO subscriber? Sign In

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts